Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $2.82 billion. The enterprise value is $1.91 billion.

Market Cap	2.82B
Enterprise Value	1.91B

Important Dates

The last earnings date was Thursday, May 9, 2024, after market close.

Earnings Date	May 9, 2024
Ex-Dividend Date	n/a

Share Statistics

RNA has 95.64 million shares outstanding.

Shares Outstanding	95.64M
Owned by Insiders (%)	5.71%
Owned by Institutions (%)	96.05%
Float	71.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	259.37
Forward PS	n/a
PB Ratio	3.39
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	175.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.47, with a Debt / Equity ratio of 0.01.

Current Ratio	12.47
Quick Ratio	n/a
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -38.00% and return on invested capital (ROIC) is -30.38%.

Return on Equity (ROE)	-38.00%
Return on Assets (ROA)	-33.10%
Return on Capital (ROIC)	-30.38%
Revenue Per Employee	$42,964
Profits Per Employee	-$903,877
Employee Count	253
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +167.94% in the last 52 weeks. The beta is 0.79, so RNA's price volatility has been lower than the market average.

Beta (1Y)	0.79
52-Week Price Change	+167.94%
50-Day Moving Average	24.99
200-Day Moving Average	12.94
Relative Strength Index (RSI)	66.37
Average Volume (30 Days)	1,199,240

Short Selling Information

Short Interest	11.39M
Short Previous Month	10.66M
Short % of Shares Out	15.59%
Short % of Float	n/a
Short Ratio (days to cover)	11.86

Income Statement

In the last 12 months, RNA had revenue of $10.87 million and -$228.68 million in losses. Loss per share was -$2.96.

Revenue	10.87M
Gross Profit	10.87M
Operating Income	-255.19M
Pretax Income	-228.68M
Net Income	-228.68M
EBITDA	-223.21M
EBIT	-228.68M
Loss Per Share	-$2.96

Full Income Statement

Balance Sheet

The company has $916.17 million in cash and $9.15 million in debt, giving a net cash position of $907.02 million or $9.48 per share.

Cash & Cash Equivalents	916.17M
Total Debt	9.15M
Net Cash	907.02M
Net Cash Per Share	$9.48
Equity / Book Value	830.90M
Book Value Per Share	8.69
Working Capital	859.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$140.48 million and capital expenditures -$3.32 million, giving a free cash flow of -$143.80 million.

Operating Cash Flow	-140.48M
Capital Expenditures	-3.32M
Free Cash Flow	-143.80M
FCF Per Share	-$1.65

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -2,347.64% and -2,103.78%.

Gross Margin	100.00%
Operating Margin	-2,347.64%
Pretax Margin	-2,103.78%
Profit Margin	-2,103.78%
EBITDA Margin	-2,053.47%
EBIT Margin	-2,103.78%
FCF Margin	-1,322.91%

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.82%
Shareholder Yield	-23.82%
Earnings Yield	-8.11%
FCF Yield	-5.10%

Analyst Forecast

The average price target for RNA is $38.29, which is 29.80% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$38.29
Price Target Difference	29.80%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	150.78%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 13.39 and a Piotroski F-Score of 3.

Altman Z-Score	13.39
Piotroski F-Score	3